



JPW

Application No. 10/792,191  
Paper Dated August 23, 2005  
Attorney Docket No.0624-040488

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/792,191 Confirmation No. 4926  
Applicant : Chun-Ying HUANG et al.  
Filed : March 3, 2004  
Title : RADIOACTIVE ARSENIC-CONTAINING  
COMPOUNDS AND THEIR USES IN THE  
TREATMENT OF TUMORS  
Group Art Unit : 1616  
Examiner : Not Yet Assigned  
Customer No. : 28289

INFORMATION DISCLOSURE STATEMENT

MAIL STOP AMENDMENT  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the requirements of 37 CFR §§ 1.56, 1.97, and 1.98, the Applicants hereby submit this Information Disclosure Statement together with a completed Form PTO/SB/08A, and one copy of the references listed thereon.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 23, 2005.

Kay E. Yetter

(Name of Person Mailing Paper)

Signature

8/23/2005

Date

{W0208716.1}


Application No. 10/792,191  
Paper Dated August 23, 2005  
Attorney Docket No.0624-040488

The references identified on Form PTO/SB/08A were cited and discussed on pages 2-5, 7-8 and 11 of the specification of the application.

Pursuant to 37 CFR § 1.97(b)(3), no fees are believed to be due with the submission of this Information Disclosure Statement, as it is being submitted before the mailing date of the first Office Action on the merits. Nevertheless, the Commissioner of Patents and Trademarks is hereby authorized to charge any additional fees, which may be required to Deposit Account No. 23-0650. One original and two (2) copies of this Information Disclosure Statement are enclosed.

Respectfully submitted,

THE WEBB LAW FIRM

By 

Russell D. Orkin  
Registration No. 25,363  
Attorney for Applicants  
700 Koppers Building  
436 Seventh Avenue  
Pittsburgh, PA 15219-1815  
Telephone: 412-471-8815  
Facsimile: 412-471-4094





Please type a plus sign (+) inside this box →

Approved for use through 10/31/2001. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

### Complete if Known

Application Number	10/792,191
Filing Date	March 3, 2004
First Named Inventor	Chun-Ying Huang
Group Art Unit	1616
Examiner Name	Not Yet Assigned
Attorney Docket Number	0624-040488

Sheet	2	2
-------	---	---

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cite and/or country where published.	T <sup>2</sup>
	1	Zhi-Xiang Shen et al, Use of Arsenic Trioxide (As <sub>2</sub> O <sub>3</sub> ) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients, BLOOD, Vol 89, No. 9, May 1, 1997: pp. 3354-3360	
	2	Zhen-Yi Wang, Arsenic Compounds as Anticancer Agents, CANCER CHEMOTHERAPY AND PHARMACOLOGY, DOI 10.1007/s002800100309, Published Online: 27 November 2001	
	3	Shen Y et al., Studies on the Clinical Efficacy and Pharmacokinetics of Low-Dose Arsenic Trioxide in the Treatment of Relapsed Acute Promyelocytic Leukemia: A Comparison With Conventional Dosage, LEUKEMIA 2001, May : 15(5): pages 735-41	
	4	Muto A. et al, A Novel Differentiation-Inducing Therapy for Acute Promyelocytic Leukemia With a Combination of Arsenic Trioxide and GM-CSF, LEUKEMIA 2001, Aug: 15(8): pages 1176-84	
	5	Guo-Qiang Chen et al., Use of Arsenic Trioxide (As <sub>2</sub> O <sub>3</sub> ) in the Treatment of Acute Promyelocytic Leukemia (APL): I. As <sub>2</sub> O <sub>3</sub> Exerts Dose-Dependent Dual Effects on APL Cells, BLOOD, Vol 89, No. 9, May 1, 1997, pages 3345-3353	
	6	Wilson H. Miller et al., Mechanisms of Action of Arsenic Trioxide <sup>1</sup> , CANCER RESEARCH 62, July 15, 2002, pages 3893-3903	
	7	Anthony J. Murgo, Clinical Trials of Arsenic Trioxide in Hematologic and Solid Tumors: Overview of the National Cancer Institute Cooperative Research and Development Studies, THE ONCOLOGIST 2001; 6 (Suppl. 2), pages 22-28	
	8	Study on Anti-Tumor Activity of Arsenic Trioxide, CHINA JOURNAL OF CHINESE MATERIA MEDICA (1999), 24(3), pages 1-3	
	9	Meral Tayan Ercan et al., Therapeutic Radiopharmaceuticals, CURRENT PHARMACEUTICAL DESIGN, 2000, 6., pages 1085-1121	
	10	Yong-Jin Chun et al., Enhancement of Radiation Response in Human Cervical Cancer Cells in Vitro and in Vivo by Arsenic Trioxide (As <sub>2</sub> O <sub>3</sub> ), FEBS LETTERS 519, (2002), pages 195-200	
	11	Samir C. Mehta et al., Targeted Drug Delivery for Boron Neutron Capture Therapy, PHARMACEUTICAL RESEARCH, Vol. 13, No. 3, 1996, pages 344-351	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.